The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Original Article
PreviousPrevious
Volume 348:277-286 January 23, 2003 Number 4
NextNext

Environmental Lead Exposure and Progression of Chronic Renal Diseases in Patients without Diabetes
Ja-Liang Lin, M.D., Dan-Tzu Lin-Tan, R.N., Kuang-Hung Hsu, Ph.D., and Chun-Chen Yu, M.D.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-PowerPoint Slide Set

Commentary
-Editorial
 by Marsden, P. A.
-Letters

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-PubMed Citation
ABSTRACT

Background Previous research suggests that environmental lead exposure correlates with age-related decreases in renal function.

Methods Two hundred two patients with chronic renal insufficiency (indicated by a serum creatinine level between 1.5 mg per deciliter and 3.9 mg per deciliter) who had a normal total-body lead burden and no history of exposure to lead were observed for 24 months. After the observation period, 64 subjects with an elevated body lead burden were randomly assigned to the chelation control groups. For three months, the patients in the chelation group received lead-chelation therapy with calcium disodium EDTA, and the control group received placebo. During the ensuing 24 months, repeated chelation therapy was administered weekly to 32 patients with high-normal body lead burdens (at least 80 µg but less than 600 µg) unless on repeated testing the body lead burden fell below 60 µg; the other 32 patients served as controls and received weekly placebo infusions for 5 weeks every 6 months. The primary end point was an increase in the serum creatinine level to 1.5 times the base-line value during the observation period. A secondary end point was the change in renal function during the intervention period.

Results The primary end point occurred in 24 patients during the observation period; the serum creatinine levels and body lead burden at base line were the most important risk factors. The glomerular filtration rate improved significantly by the end of the 27-month intervention period in patients receiving chelation therapy: the mean (±SD) change in the glomerular filtration rate in the patients in the chelation group was 2.1±5.7 ml per minute per 1.73 m2 of body-surface area, as compared with –6.0±5.8 ml per minute per 1.73 m2 of body-surface area in the controls (P<0.001). The rate of decline in the glomerular filtration rate in the chelation group was also lower than that in the controls during the 24-month period of repeated chelation therapy or placebo.

Conclusions Low-level environmental lead exposure may accelerate progressive renal insufficiency in patients without diabetes who have chronic renal disease. Repeated chelation therapy may improve renal function and slow the progression of renal insufficiency.


Source Information

From the Divisions of Nephrology and Clinical Toxicology, Chang Gung Memorial Hospital, Lin-Kou Medical Center, Medical College of Chang Gung University (J.-L.L., D.-T.L.-T., C.-C.Y.); and the Laboratory for Epidemiology, Department of Health Care Management, Chang Gung University (K.-H.H.), Taipei, Taiwan.

Address reprint requests to Dr. Lin at the Poison Center and Division of Nephrology, Chang Gung Memorial Hospital, 199 Tung Hwa North Rd., Taipei, Taiwan, or at jllin99{at}hotmail.com.

Full Text of this Article


Related Letters:

Environmental Lead Exposure and Chronic Renal Disease
Owda A. K., Alam M. G., Shah S. V., Lopes A. A., Port F. K., Elinder C.-G., Alvestrand A., Lin J.-L., Yu C.-C., Lin-Tan D.-T.
Extract | Full Text | PDF  
N Engl J Med 2003; 348:1810-1812, May 1, 2003. Correspondence

This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.